Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab Plus First-line Combination Chemotherapy in HER2-Expressing GI Cancers
NCT03929666Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2019
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of zanidatamab in gastroesophageal adenocarcinoma, biliary tract cancer (BTC), colorectal cancer (CRC), sponsored by Jazz Pharmaceuticals plc. Started Aug 2019; status: completed.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal adenocarcinomabiliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03929666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929666.